This case discusses a patient who presented with immune thrombocytopenia purpura (ITP) one week after COVID-19 vaccination, introducing ITP as a consideration for a potential, but rare, adverse reaction to COVID-19 vaccination.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385179 | PMC |
http://dx.doi.org/10.1002/ccr3.4689 | DOI Listing |
Sci Rep
December 2024
Department of Public Health, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.
Healthcare workers are exposed to a high risk of COVID-19 infection due to close contact with infected patients in healthcare centers. This study aimed to investigate the level of exposure and risk of COVID-19 virus infection among healthcare workers working in primary healthcare centers in Khuzestan province, Iran. This cross-sectional study was conducted among 599 healthcare workers working in primary healthcare centers in the northern region of Khuzestan province, Iran, in 2022.
View Article and Find Full Text PDFBMC Infect Dis
December 2024
Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, Casablanca, 20360, Morocco.
To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument.
View Article and Find Full Text PDFBMC Infect Dis
December 2024
KEMRI-Wellcome Trust Research Programme, P.O. Box 230, Kilifi, Kenya.
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and October 2024 using sera from representative samples of the Kenyan population.
View Article and Find Full Text PDFVaccine
December 2024
Scientific Advisor and Emeritus Director, National Influenza Centre, Valladolid, 47010, Spain.
Clin Microbiol Infect
December 2024
National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ministry of Health, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Objectives: Most studies on long-term sequelae of SARS-CoV-2-infection in children were conducted pre-Omicron and pre-dated vaccination rollout. We examined long-term risk of new-incident multi-systemic sequelae after SARS-CoV-2 Delta/Omicron infection in a multi-ethnic Asian pediatric population.
Methods: Retrospective cohort study of Singaporean children aged 1- 17 years infected during Delta/Omicron BA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!